General Information
Note: Estimated new cases and deaths from vulvar cancer in the United States in 2004:[1] - New cases: 3,970.
- Deaths: 850.
Vulvar cancer is
primarily a disease of elderly women but has been observed in premenopausal
women as well. It is most commonly squamous cell carcinoma in type, although
other histologic types do occur. Vulvar cancer is highly curable when diagnosed in an early stage. Survival is
most dependent on the pathologic status of the inguinal nodes. In patients with operable disease without nodal involvement, the overall survival rate is 90%; however,
in patients with nodal involvement, the overall 5-year survival rate is approximately 50%
to 60%.[2] Risk factors for node metastasis are clinical node status, age, degree
of differentiation, tumor stage, tumor thickness, depth of stromal invasion,
and presence of capillary-lymphatic space invasion.[2-6] Overall, about 30% of
patients with operable disease have nodal spread. A multifactorial analysis of risk factors
in squamous vulvar cancer demonstrated that nodal status and primary lesion
diameter, when considered together, were the only variables associated with
prognosis. Patients with negative inguinal nodes and lesions no more than 2 cm
had a 98% 5-year survival rate, while those with any size lesion with 3 or more
unilateral nodes or 2 or more bilateral nodes had a 29% 5-year survival rate.
Intermediate groups with intermediate survival were also identified.[2] These
discriminants were most useful within FIGO stage III disease.
In many cases, the development of vulvar cancer is preceded by condyloma or
squamous dysplasias. The prevailing evidence favors human papillomavirus (HPV)
as a causative factor in genital tract carcinomas. The labia majora is the most common site of
involvement and accounts for about 50% of cases. The labia minora
accounts for 15% to 20% of cases. The clitoris and Bartholin’s glands are less
frequently involved.[7]
The pattern of spread is influenced by the histology. Well-differentiated
lesions tend to spread along the surface with minimal invasion, while
anaplastic lesions are more likely to be deeply invasive. Spread beyond the
vulva is either to adjacent organs such as the vagina, urethra, and anus, or
via the lymphatics to the inguinal and femoral lymph nodes, followed by the deep
pelvic nodes. Hematogenous spread appears to be uncommon.
References
- American Cancer Society.: Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society, 2004. Also available online. Last accessed May 13, 2004.
- Homesley HD, Bundy BN, Sedlis A, et al.: Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 164 (4): 997-1003; discussion 1003-4, 1991.
[PUBMED Abstract]
- Boyce J, Fruchter RG, Kasambilides E, et al.: Prognostic factors in carcinoma of the vulva. Gynecol Oncol 20 (3): 364-77, 1985.
[PUBMED Abstract]
- Sedlis A, Homesley H, Bundy BN, et al.: Positive groin lymph nodes in superficial squamous cell vulvar cancer. A Gynecologic Oncology Group Study. Am J Obstet Gynecol 156 (5): 1159-64, 1987.
[PUBMED Abstract]
- Binder SW, Huang I, Fu YS, et al.: Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol 37 (1): 9-16, 1990.
[PUBMED Abstract]
- Homesley HD, Bundy BN, Sedlis A, et al.: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) Gynecol Oncol 49 (3): 279-83, 1993.
[PUBMED Abstract]
- Macnab JC, Walkinshaw SA, Cordiner JW, et al.: Human papillomavirus in clinically and histologically normal tissue of patients with genital cancer. N Engl J Med 315 (17): 1052-8, 1986.
[PUBMED Abstract]
Back to Top
Next Section > |